Overview

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Status:
Completed

Trial end date:
2018-11-05

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual components given in separate tablets (Reference, R) when administered together after a high-fat, high-calorie meal. The assessment of safety and tolerability will be the secondary objective of this trial.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Eli Lilly and Company

Treatments:

Empagliflozin
Linagliptin
Metformin